Mylan on Tuesday earned Food and Drug Administration approval for its generic version of Teva's multiple sclerosis drug Copaxone.
Here are three things to know
1. Mylan's glatiramer acetate injection is intended to treat patients with relapsing forms of MS.
2. The FDA approved two forms of the generic drug — a larger dose injected three times a week and a smaller dose injected daily.
3. Mylan will launch a patient support service program in conjunction with the generic drug, which will include an interactive mobile app, in-home injection training and co-pay assistance for eligible patients, among other features.